版本:
中国

BRIEF-Durect Corp, Sandoz AG sign U.S. development and commercialization agreement for posimir

May 11 Durect Corp

* Durect Corp - co and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for U.S. for posimir

* Durect Corp - under terms of agreement, Sandoz will make an upfront payment to Durect of $20 million

* Durect Corp - co remain's responsible for conducting persist Phase 3 trial, comparing posimir to bupivacaine HC1 after laparoscopic gall bladder removal

* Durect Corp - company anticipates completing dosing patients in Q3/17 for persist Phase 3 trial and expects to have top-line data shortly thereafter

* Durect - deal also includes potential for up to additional $43 million in development, regulatory milestones, up to additional $230 million in sales based milestones Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐